阿霉素持续静脉输注联合盖诺治疗晚期乳腺癌临床观察

目的：观察阿霉素持续静脉输注联合国产长春瑞滨（盖诺NVB）治疗晚期乳腺癌的疗效及毒副反应，探讨治疗方式改变在化疗中的价值。方法：32例晚期乳腺癌患者，用NA方案：NVB25mg／m^2 ivgtt d1，8、ADM50mg／m^2 civ 96hd1-4。每28天为一周期，至少2周期后评价疗效。观察疗效及毒副反应。结果：32例患者均随访。总共用药170周期，平均5．3周期。CR5例，PR18例，RR（CR＋PR）71．9％。初治、复治有效率分别为73．3％、70．6％，二者间无显著性差异（P〉0．05）。中位缓解期8．2个月。主要毒副反应为白细胞降低，发生率100％（32／32），32例中Ⅲ～Ⅳ度下降15例（46．9％）；恶心、呕吐23例（71．9％），Ⅲ～Ⅳ度4例（12．5％）；均发生脱发，Ⅲ～Ⅳ度5例（15．6％）；口腔炎16例（50．0％），Ⅲ～Ⅳ度4例（12．5％）；静脉炎2例（6．2％），均为Ⅰ度；心脏毒性发生3例（9．4％），为Ⅰ、Ⅱ度不等。无治疗相关性死亡。结论：阿霉素持续静脉输注与盖诺联合治疗晚期转移性乳腺癌疗效明确，毒副反应可以耐受，远期疗效值得进一步研究。

Combination Chemotherapy with Vinorelbin and 96h Infusion of ADM for Metastatic Breast Cancer

Objective：To investigate the efficacy of combined chemotherapy based on NA, ADM as a 96h continous intravenous infusion on breast cancer,and its side-effects. Methods： NA scheme was formed with ADM constant intervenous injection in 50mg/m^2 for 96h in 32 patients with metastatic breast cancer with 28 days as one cycle,after at least 2 cycles of treatment. The therapeutic efficacy and clinical symptoms were evaluated. Results：The overall response rate for the whole group of patients was 71. 9%. The primary group obtained effective rate by 73.3%, relapse group by 70.6% ,and side-reactions were tolerable. Toxicity was tolerable. There was no treatment-related death. Conclusion： The chemotherapy has a high effective rate with acceptable toxicity in patient with metastatic breast cancer.